{"id":"https://openalex.org/W4408020522","doi":"https://doi.org/10.1016/j.xkme.2025.100988","title":"Effectiveness of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in US Clinical Practice With Comparison to Historical Control Data","display_name":"Effectiveness of Tolvaptan for Autosomal Dominant Polycystic Kidney Disease in US Clinical Practice With Comparison to Historical Control Data","publication_year":2025,"publication_date":"2025-02-27","ids":{"openalex":"https://openalex.org/W4408020522","doi":"https://doi.org/10.1016/j.xkme.2025.100988","pmid":"https://pubmed.ncbi.nlm.nih.gov/40242785"},"language":"en","primary_location":{"id":"doi:10.1016/j.xkme.2025.100988","doi":"https://doi.org/10.1016/j.xkme.2025.100988","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.xkme.2025.100988","pdf_url":null,"source":{"id":"https://openalex.org/S4210206143","display_name":"Kidney Medicine","issn_l":"2590-0595","issn":["2590-0595"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Kidney Medicine","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://doi.org/10.1016/j.xkme.2025.100988","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5085269683","display_name":"Ronald D. Perrone","orcid":"https://orcid.org/0000-0002-4963-1132","observed_orcids":["https://orcid.org/0000-0002-4963-1132"]},"institutions":[{"id":"https://openalex.org/I1290900354","display_name":"Tufts Medical Center","ror":"https://ror.org/002hsbm82","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1290900354"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Ronald D. Perrone","raw_affiliation_strings":["Division of Nephrology, Tufts Medical Center, Boston, MA"],"raw_orcid":"https://orcid.org/0000-0002-4963-1132","affiliations":[{"raw_affiliation_string":"Division of Nephrology, Tufts Medical Center, Boston, MA","institution_ids":["https://openalex.org/I1290900354"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081230199","display_name":"Diana Garbinsky","orcid":"https://orcid.org/0000-0002-3214-2527","observed_orcids":["https://orcid.org/0000-0002-3214-2527"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Diana Garbinsky","raw_affiliation_strings":["RTI Health Solutions, Research Triangle Park, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions, Research Triangle Park, NC","institution_ids":["https://openalex.org/I4210120329"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5057887317","display_name":"Sasikiran Nunna","orcid":"https://orcid.org/0000-0002-8006-7306","observed_orcids":["https://orcid.org/0000-0002-8006-7306"]},"institutions":[{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Sasikiran Nunna","raw_affiliation_strings":["Otsuka Pharmaceutical Development & Commercialization Inc, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka Pharmaceutical Development & Commercialization Inc, Rockville, MD","institution_ids":["https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5056194464","display_name":"Hema Kannan Gandhi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hema K. Gandhi","raw_affiliation_strings":["Otsuka Pharmaceutical Development & Commercialization Inc, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka Pharmaceutical Development & Commercialization Inc, Rockville, MD","institution_ids":["https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5112284282","display_name":"Ancilla W. Fernandes","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4405268153","display_name":"Otsuka Pharmaceutical Development & Commercialization, Inc. (United States)","ror":"https://ror.org/001nxvg84","country_code":"US","type":"company","lineage":["https://openalex.org/I4405268153"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ancilla W. Fernandes","raw_affiliation_strings":["Otsuka Pharmaceutical Development & Commercialization Inc, Rockville, MD"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Otsuka Pharmaceutical Development & Commercialization Inc, Rockville, MD","institution_ids":["https://openalex.org/I4405268153"]}]},{"author_position":"middle","author":{"id":null,"display_name":"Gabriela Burgos","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I1342911587","display_name":"Oracle (United States)","ror":"https://ror.org/006c77m33","country_code":"US","type":"company","lineage":["https://openalex.org/I1342911587"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Gabriela Burgos","raw_affiliation_strings":["Oracle Life Sciences, Austin, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oracle Life Sciences, Austin, TX","institution_ids":["https://openalex.org/I1342911587"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5005941041","display_name":"Abisola Olopoenia","orcid":"https://orcid.org/0000-0001-5877-5237","observed_orcids":["https://orcid.org/0000-0001-5877-5237"]},"institutions":[{"id":"https://openalex.org/I1342911587","display_name":"Oracle (United States)","ror":"https://ror.org/006c77m33","country_code":"US","type":"company","lineage":["https://openalex.org/I1342911587"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Abisola Olopoenia","raw_affiliation_strings":["Oracle Life Sciences, Austin, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oracle Life Sciences, Austin, TX","institution_ids":["https://openalex.org/I1342911587"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5035941290","display_name":"Marc DeCongelio","orcid":"https://orcid.org/0009-0004-5486-5584","observed_orcids":["https://orcid.org/0009-0004-5486-5584"]},"institutions":[{"id":"https://openalex.org/I1342911587","display_name":"Oracle (United States)","ror":"https://ror.org/006c77m33","country_code":"US","type":"company","lineage":["https://openalex.org/I1342911587"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Marc DeCongelio","raw_affiliation_strings":["Oracle Life Sciences, Austin, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oracle Life Sciences, Austin, TX","institution_ids":["https://openalex.org/I1342911587"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5044858482","display_name":"Martine C. Maculaitis","orcid":"https://orcid.org/0000-0001-8388-5315","observed_orcids":["https://orcid.org/0000-0001-8388-5315"]},"institutions":[{"id":"https://openalex.org/I1342911587","display_name":"Oracle (United States)","ror":"https://ror.org/006c77m33","country_code":"US","type":"company","lineage":["https://openalex.org/I1342911587"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Martine C. Maculaitis","raw_affiliation_strings":["Oracle Life Sciences, Austin, TX"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Oracle Life Sciences, Austin, TX","institution_ids":["https://openalex.org/I1342911587"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5046482086","display_name":"Xiaolei Zhou","orcid":"https://orcid.org/0000-0002-7992-637X","observed_orcids":["https://orcid.org/0000-0002-7992-637X","https://orcid.org/0000-0002-7293-4641"]},"institutions":[{"id":"https://openalex.org/I4210120329","display_name":"RTI Health Solutions","ror":"https://ror.org/032nh7f71","country_code":"US","type":"nonprofit","lineage":["https://openalex.org/I137902535","https://openalex.org/I170897317","https://openalex.org/I180297670","https://openalex.org/I4210120329"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaolei Zhou","raw_affiliation_strings":["RTI Health Solutions, Research Triangle Park, NC"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"RTI Health Solutions, Research Triangle Park, NC","institution_ids":["https://openalex.org/I4210120329"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5085269683"],"corresponding_institution_ids":["https://openalex.org/I1290900354"],"apc_list":{"value":2590,"currency":"USD","value_usd":2590},"apc_paid":{"value":2590,"currency":"USD","value_usd":2590},"fwci":2.1317,"has_fulltext":false,"cited_by_count":4,"citation_normalized_percentile":{"value":0.85731998,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":97},"biblio":{"volume":"7","issue":"5","first_page":"100988","last_page":"100988"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11412","display_name":"Genetic and Kidney Cyst Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11412","display_name":"Genetic and Kidney Cyst Diseases","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10408","display_name":"Chronic Kidney Disease and Diabetes","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2727","display_name":"Nephrology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12049","display_name":"Tuberous Sclerosis Complex Research","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/tolvaptan","display_name":"tolvaptan","score":0.9900000095367432},{"id":"https://openalex.org/keywords/autosomal-dominant-polycystic-kidney-disease","display_name":"autosomal dominant polycystic kidney disease","score":1.0},{"id":"https://openalex.org/keywords/real-world-effectiveness","display_name":"real-world effectiveness","score":0.8149999976158142},{"id":"https://openalex.org/keywords/estimated-glomerular-filtration-rate-decline","display_name":"estimated glomerular filtration rate decline","score":0.9290000200271606},{"id":"https://openalex.org/keywords/historical-control-comparison","display_name":"historical control comparison","score":0.5899999737739563},{"id":"https://openalex.org/keywords/nephrology-practice","display_name":"nephrology practice","score":0.6629999876022339},{"id":"https://openalex.org/keywords/antihypertensive-therapy","display_name":"antihypertensive therapy","score":0.7879999876022339},{"id":"https://openalex.org/keywords/chronic-kidney-disease-progression","display_name":"chronic kidney disease progression","score":0.578000009059906},{"id":"https://openalex.org/keywords/antifibrotic-therapy","display_name":"antifibrotic therapy","score":0.4569999873638153}],"concepts":[{"id":"https://openalex.org/C2780615674","wikidata":"https://www.wikidata.org/wiki/Q426132","display_name":"Tolvaptan","level":3,"score":0.9639757871627808},{"id":"https://openalex.org/C2779974597","wikidata":"https://www.wikidata.org/wiki/Q28448986","display_name":"Clinical Practice","level":2,"score":0.47419172525405884},{"id":"https://openalex.org/C2775924081","wikidata":"https://www.wikidata.org/wiki/Q55608371","display_name":"Control (management)","level":2,"score":0.41645801067352295},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.40438342094421387},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.31340765953063965},{"id":"https://openalex.org/C41008148","wikidata":"https://www.wikidata.org/wiki/Q21198","display_name":"Computer science","level":0,"score":0.28476130962371826},{"id":"https://openalex.org/C512399662","wikidata":"https://www.wikidata.org/wiki/Q3505712","display_name":"Family medicine","level":1,"score":0.16173329949378967},{"id":"https://openalex.org/C154945302","wikidata":"https://www.wikidata.org/wiki/Q11660","display_name":"Artificial intelligence","level":1,"score":0.1477161943912506},{"id":"https://openalex.org/C2778198053","wikidata":"https://www.wikidata.org/wiki/Q181754","display_name":"Heart failure","level":2,"score":0.0}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1016/j.xkme.2025.100988","doi":"https://doi.org/10.1016/j.xkme.2025.100988","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.xkme.2025.100988","pdf_url":null,"source":{"id":"https://openalex.org/S4210206143","display_name":"Kidney Medicine","issn_l":"2590-0595","issn":["2590-0595"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Kidney Medicine","raw_type":"journal-article"},{"id":"pmid:40242785","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/40242785","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Kidney medicine","raw_type":"Journal Article"},{"id":"pmh:oai:pubmedcentral.nih.gov:12002913","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/12002913","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Kidney Med","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1016/j.xkme.2025.100988","doi":"https://doi.org/10.1016/j.xkme.2025.100988","is_oa":true,"landing_page_url":"https://doi.org/10.1016/j.xkme.2025.100988","pdf_url":null,"source":{"id":"https://openalex.org/S4210206143","display_name":"Kidney Medicine","issn_l":"2590-0595","issn":["2590-0595"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","jufo-1","ki-jl-1","norway-1","poland-20"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Kidney Medicine","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"sustainable_development_goals_aurora":[],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320306605","display_name":"American Society of Nephrology","ror":"https://ror.org/014pcm848"},{"id":"https://openalex.org/F4320308623","display_name":"MDC","ror":"https://ror.org/01sn6ez28"},{"id":"https://openalex.org/F4320333791","display_name":"Otsuka Pharmaceutical Development and Commercialization","ror":"https://ror.org/001nxvg84"},{"id":"https://openalex.org/F4320337357","display_name":"National Institute of Diabetes and Digestive and Kidney Diseases","ror":"https://ror.org/00adh9b73"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":15,"referenced_works":["https://openalex.org/W1981747359","https://openalex.org/W1997286719","https://openalex.org/W2052771648","https://openalex.org/W2077093911","https://openalex.org/W2101067234","https://openalex.org/W2112643254","https://openalex.org/W2143990369","https://openalex.org/W2604855121","https://openalex.org/W2765795120","https://openalex.org/W3093085210","https://openalex.org/W3126606011","https://openalex.org/W3182939079","https://openalex.org/W4320498794","https://openalex.org/W4385810699","https://openalex.org/W4403463896"],"related_works":["https://openalex.org/W2899084033","https://openalex.org/W2748952813","https://openalex.org/W3031052312","https://openalex.org/W2583712976","https://openalex.org/W4389568370","https://openalex.org/W3032375762","https://openalex.org/W2084006555","https://openalex.org/W1995515455","https://openalex.org/W2080531066","https://openalex.org/W4212882181"],"abstract_inverted_index":{"Rationale":[0],"&":[1,118],"Objective":[2],"Data":[3],"from":[4,67,93,279],"clinical":[5,20,98,201,300,327],"practice":[6],"are":[7,315,339,365],"needed":[8],"to":[9,128,169,271,342,384],"characterize":[10],"the":[11,16,32,163,304,316,404],"effectiveness":[12,33],"of":[13,19,34,51,96,105,111,131,158,180,189,236,277,306,369],"pharmacotherapy":[14],"outside":[15],"controlled":[17,307,313],"setting":[18],"trials":[21,314],"but":[22,322],"lack":[23],"an":[24,77],"untreated":[25],"placebo":[26],"group":[27,406],"for":[28,36,83,101,139,319],"comparison.":[29],"To":[30,372],"assess":[31,373],"tolvaptan":[35,90,164,171,351,391,421],"autosomal":[37,359],"dominant":[38,360],"polycystic":[39,361],"kidney":[40,210,353,362],"disease":[41,211,363],"(ADPKD)":[42],"in":[43,76,148,241,255,298,356,376,398,403],"nephrology":[44,378],"practice,":[45,301,379],"we":[46,380],"performed":[47],"a":[48,58,94,229,261,429],"chart":[49],"review":[50],"US":[52,72,382],"patients":[53,84,243,357,389],"and":[54,115,126,195,208,221,226,282,336],"compared":[55,227,396],"it":[56],"with":[57,85,89,162,294,303,358,407],"historical":[59,245,409],"matched":[60,198,214,216,224,408,418],"control":[61,81,288],"cohort.":[62],"Study":[63],"Design":[64],"Patient":[65],"data":[66,82,125,347,387],"charts":[68],"were":[69,91,146,197],"provided":[70,123],"by":[71,247],"nephrologists":[73,383],"who":[74,364,411],"participated":[75],"online":[78],"survey.":[79],"Historical":[80,143,175],"ADPKD":[86,97],"not":[87,413],"treated":[88],"extracted":[92],"database":[95],"studies":[99],"(Consortium":[100],"Radiologic":[102],"Imaging":[103],"Studies":[104],"Polycystic":[106,112],"Kidney":[107,113],"Disease,":[108,114],"HALT":[109],"Progression":[110],"OVERTURE).":[116],"Setting":[117],"Participants":[119],"Nephrologist":[120],"respondents":[121],"(n=57)":[122],"baseline":[124,200],"up":[127],"4":[129],"years":[130],"follow-up":[132,431],"on":[133,199,388],"estimated":[134,399,423],"glomerular":[135,400,424],"filtration":[136,401,425],"rate":[137,188,235,402,426],"(eGFR)":[138],"tolvaptan-treated":[140,242,405],"adults":[141,147],"(n=149).":[142],"ADPKD-affected":[144],"controls":[145,176,196,410],"Mayo":[149],"imaging":[150],"risk":[151,157,368],"classes":[152],"1C\u20131E":[153],"(ie,":[154],"at":[155,366],"increased":[156,367],"rapid":[159,370],"progression,":[160],"consistent":[161,302],"indication).":[165],"Exposure":[166],"Cases":[167,194],"had":[168],"receive":[170,414],"continuously":[172],"for\u22652":[173],"years.":[174],"received":[177],"nontolvaptan":[178],"standard":[179,318],"care,":[181],"including":[182],"various":[183],"antihypertensive":[184],"regimens.":[185],"Outcome":[186],"Annual":[187],"eGFR":[190,222,237,296],"change.":[191],"Analytical":[192],"Approach":[193],"characteristics":[202],"(matched":[203],"set":[204,217,256],"A:":[205],"age,":[206,219],"sex,":[207,220],"chronic":[209],"stage":[212],"[110":[213],"pairs];":[215],"B:":[218],"[98":[223],"pairs])":[225],"using":[228],"mixed":[230],"model.":[231],"Results":[232],"The":[233],"annual":[234],"decline":[238,297,355,397,427],"was":[239,292],"slower":[240,295],"versus":[244],"controls,":[246],"1.40mL/min/1.73m":[248],"2":[249,265],"(95%":[250,268],"CI,":[251,269],"0.05-2.74;":[252],"P":[253,273],"=0.04)":[254],"A.":[257],"Set":[258],"B":[259],"demonstrated":[260,349],"similar":[262],"trend:":[263],"1.18mL/min/1.73m":[264],"per":[266],"year":[267],"\u22120.22":[270],"2.58;":[272],"=0.10).":[274],"Limitations":[275],"Risk":[276],"bias":[278],"convenience":[280],"sampling":[281],"potential":[283],"residual":[284],"confounding":[285],"after":[286],"case/historical":[287],"matching.":[289],"Conclusions":[290],"Tolvaptan":[291],"associated":[293],"routine":[299,326],"results":[305],"trials.":[308],"Plain":[309],"Language":[310],"Summary":[311],"Randomized,":[312],"gold":[317],"evaluating":[320],"pharmacotherapy,":[321],"evidence":[323],"collected":[324],"under":[325,392],"conditions":[328],"can":[329],"answer":[330],"questions":[331],"about":[332],"drug":[333],"effectiveness,":[334],"safety,":[335],"value":[337],"that":[338,350],"particularly":[340],"relevant":[341],"everyday":[343],"medical":[344],"practice.":[345],"Trial":[346],"have":[348],"slows":[352],"function":[354],"progression.":[371],"treatment":[374],"effect":[375],"regular":[377],"invited":[381],"provide":[385],"anonymized":[386],"receiving":[390],"their":[393],"care.":[394],"We":[395],"did":[412],"tolvaptan.":[415],"Across":[416],"multiple":[417],"analysis":[419],"sets,":[420],"slowed":[422],"over":[428],"4-year":[430],"period.":[432]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":2}],"updated_date":"2026-10-16T09:59:22.235173","created_date":"2025-02-28T00:00:00"}